Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

M Cavo, L Pantani, A Pezzi, MT Petrucci, F Patriarca, F Di Raimondo, G Marzocchi, M Galli, V Montefusco, E Zamagni, B Gamberi, P Tacchetti, A Brioli, AA Palumbo, Pieter Sonneveld

Research output: Contribution to journalArticleAcademicpeer-review

51 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)2429-2431
Number of pages3
Issue number12
Publication statusPublished - 2015

Research programs

  • EMC MM-02-41-03

Cite this